More News: First-in-class Keytruda approved for melanoma
View web version
Drug Showcase
BELEODAQ® (belinostat) for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This slideshow reviews drug information for BELEODAQ® (belinostat), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 17: Clinical Safety and Efficacy
Slide 23: Drug Storage and Supply Slide 25: References
From the Advisory Board
The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma
By
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
By Adam M. Brufsky
Latest News
Researchers Use Bacillus Anthracis to Deliver Antibodies to Cancer Cells
Pleiotrophin Key to Accelerating Blood System Recovery
Higher Lipoprotein Cholesterol May Protect Against Cancer

For more on the latest research and developments in oncology, visit our News section.



Get more updates
with our mobile app!

Want to receive emails specific to your profession and specialty? Click here to complete your profile.





Subscribe
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

Unsubscribe
To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001